GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Other Operating Expense

Bio-Techne (BSP:T1CH34) Other Operating Expense : R$164 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Other Operating Expense?

Bio-Techne's Other Operating Expense for the three months ended in Mar. 2024 was R$-0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was R$164 Mil.

Bio-Techne's quarterly Other Operating Expense increased from Sep. 2023 (R$-0 Mil) to Dec. 2023 (R$0 Mil) but then declined from Dec. 2023 (R$0 Mil) to Mar. 2024 (R$-0 Mil).

Bio-Techne's annual Other Operating Expense increased from Jun. 2021 (R$149 Mil) to Jun. 2022 (R$174 Mil) but then declined from Jun. 2022 (R$174 Mil) to Jun. 2023 (R$164 Mil).


Bio-Techne Other Operating Expense Historical Data

The historical data trend for Bio-Techne's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Other Operating Expense Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.52 146.69 149.01 174.28 164.47

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 164.47 - - -

Bio-Techne Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$164 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Techne Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (BSP:T1CH34) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines